<DOC>
	<DOCNO>NCT01519336</DOCNO>
	<brief_summary>This randomize , open-label , multiple-dose , 2-period crossover study evaluate potential drug-drug interaction darunavir danoprevir administer together low-dose ritonavir healthy volunteer . In Period 1 , subject randomize receive either darunavir danoprevir together low-dose ritonavir 10 day . In Period 2 , subject receive darunavir plus danoprevir together ritonavir 10 day . Anticipated time study treatment 20 day .</brief_summary>
	<brief_title>A Study Drug-Drug Interaction Between Darunavir Danoprevir Administered Together With Low-Dose Ritonavir Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Lactams</mesh_term>
	<criteria>Healthy nonsmoking male female adult , 18 55 year age , inclusive Healthy status define absence evidence active chronic disease Medical history without major , recent , ongoing pathology Weight &gt; /= 55 kg Body mass index ( BMI ) 18.0 32.0 kg/m2 Ability willingness abstain alcohol , xanthinecontaining beverage food ( coffee , tea , cola , chocolate , `` energy drink '' ) 72 hour prior entry clinical site center discharge Females childbearing potential male female partner childbearing potential must agree use 2 form contraception , one must barrier method , study 90 day last drug administration . Acceptable barrier form contraception condom diaphragm ; acceptable nonbarrier form contraception study nonhormonal intrauterine device ( IUD ) and/or spermicide Pregnant lactating female male female partner pregnant lactate Any history clinically significant cardiovascular cerebrovascular disease , hypertension , and/or infection Positive test drug abuse screen prior admission clinical site study period Positive hepatitis B , hepatitis C HIV infection Current smoker subject discontinue smoke less 6 month prior first dose study medication Use hormonal contraceptive within 30 day first dose study medication History clinically significant drugrelated allergy ( anaphylaxis ) hepatotoxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>